MAPT and Alzheimer disease: P021 treatment significantly reduced tau pathology both at moderate and severe stages of the pathology in 3xTg-AD mice (Fig. 5), however, the effect of P021 on Aβ pathology was limited to a significant decrease in soluble Aβ levels and a trend towards reduction in Aβ plaque load in CA1 region of hippocampus, consistent with reduction in Aβ generation and not clearance (Fig. 6) [99].